期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

来氟米特联合益肾蠲痹丸治疗类风湿关节炎的临床观察 被引量：8

暂未订购
导出
摘要 目的:通过临床随机对照研究,评价来氟米特联合益肾蠲痹丸治疗类风湿关节炎的有效性及安全性。方法:将纳入标准的100例患者随机分为治疗组来氟米特+益肾蠲痹丸治疗,对照组来氟米特+甲氨蝶呤治疗,分别检测治疗前、治疗后12个月主观及客观指标。结果:治疗12个月后,治疗组有效率为90.3%,对照组有效率为85.0%,两组总体疗效差异有统计学意义(P<0.05);其中ESR、CRP、晨僵时间、VAS、HAQ等检测指标治疗前后有统计学意义(P<0.05)。结论:中西结合治疗类风湿关节炎疗效显著,副作用少,能明显提高患者生存质量。
作者 方海燕 姚兴琼
机构地区 高台县人民医院中医科 民乐县新天镇卫生院
出处 《甘肃医药》 2014年第2期117-119,共3页 Gansu Medical Journal
关键词 类风湿关节炎 来氟米特 益肾蠲痹丸 疗效 观察
分类号 R593.22 [医药卫生—内科学]
  • 相关文献

参考文献10

  • 1Klareskog L,Catrina AI,Paget S. Rheumatoidarthritis[J].{H}LANCET,2009.659-672.
  • 2Strangfeld A,Hierse F,Kekow J. Comparative effectiveness of tumour necrosis factor a inhibitors in combination with either methotrexate or leflunmide[J].{H}ANNALS OF THE RHEUMATIC DISEASES,2009,(12):1856-1862.
  • 3Finckh A,Dehler S,Gabay C. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis:a population-based study[J].{H}ANNALS OF THE RHEUMATIC DISEASES,2009,(1):33-39.
  • 4董怡.抗风湿药物的疗效评价[J].中国新药杂志,2001,10(7):549-550. 被引量：2
  • 5闫慧明,王永福.不同年龄类风湿关节炎患者临床特征分析[J].中国全科医学,2012,15(20):2259-2261. 被引量：23
  • 6Metaha D,Neogi T,Silman AJ. 2010 Rheumatoid arthritis classification cirteira:all American College of Rheumatology/European League Against Rheumatism collaborative initiative[J].{H}ANNALS OF THE RHEUMATIC DISEASES,2010,(9):2569-2581.
  • 7徐建华,姚寿林.类风湿关节炎的诊治进展[J].内科急危重症杂志,2010,16(6):281-284. 被引量：7
  • 8许推钧.桂芍知母汤加味治疗早期类风湿性关节炎临床疗效[D]{H}成都:成都中医药大学,2009.
  • 9Smolen JS,Landew R,Breedveld FC. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic durgs[J].{H}ANNALS OF THE RHEUMATIC DISEASES,2010.946-975.
  • 10鲍春德,黄文群,陈顺乐,顾越英.来氟米特治疗类风湿关节炎双盲随机对照研究[J].中华风湿病学杂志,2000,4(1):44-46. 被引量：70

二级参考文献29

  • 1姜志勇,刘海英,刘正民,刘云锋,韦茹,曾华松.瓜氨酸合成蛋白抗体等三种抗体联合检测对类风湿关节炎的诊断意义[J].中国误诊学杂志,2009,9(1):6-8. 被引量：7
  • 2[1]Felson DT,Andevson JJ,Boers M,et al.The American College of Rheumatology preliminary core set disease activity measures for rheumatoid arthritis clinical trials[J].Arthritis Rheum,1993,35∶729-740.
  • 3[2]Van Riel Plcm.Provisional guidelines for measuring disease activity in clinical trials in rheumatoid arthritis[J].Br J Rheumatol,1994,31∶793-794.
  • 4[3]FDA.Giudelines for the clinical evaluation of anti-inflammatory and antirheumatic drugs (adults and children)[S].April,1988.
  • 5[4]Paulus HE,Egger MJ,Wand JR,et al.Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs based on findings in patients with placebo[J].Arthritis Rheum,1990,33∶477-484.
  • 6[5]Felson DT,Anderson JJ,Boers M,et al.American College of Rheumatology preliminary defination of improvement in rheumatoid arthritis[J].Arthritis Rheum,1995,38∶727-735.
  • 7[6]Pincus T,Stein M.ACR 20:clinical or statistical significance[J].Arthritis Rheum,1999,42∶1572-1575.
  • 8Schellekens GA,Visser H,de Jong BA,et al.The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.Arthritis Rheum,2000,43:155.
  • 9Aletaha D,Neogi T,Silman AJ,et al.2010 rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative.Ann Rheum Dis,2010,69:1580.
  • 10Gaujoux-Viala C,Smolen JS,Landewé R,et al.Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs:a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.Ann Rheum Dis,2010,69:1004.

共引文献98

同被引文献95

引证文献8

二级引证文献116

甘肃医药
2014年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部